Omnicell, Inc. (NASDAQ:OMCL) Receives Average Rating of “Hold” from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been assigned a consensus rating of “Hold” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $42.20.

A number of research analysts have issued reports on OMCL shares. Barclays started coverage on Omnicell in a report on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 price objective for the company. Wells Fargo & Company cut their price target on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a report on Friday, February 9th. Finally, Benchmark decreased their price objective on shares of Omnicell from $42.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, February 9th.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently added to or reduced their stakes in the stock. Covestor Ltd lifted its position in shares of Omnicell by 65.6% during the third quarter. Covestor Ltd now owns 1,355 shares of the company’s stock worth $61,000 after purchasing an additional 537 shares in the last quarter. Acadian Asset Management LLC bought a new position in Omnicell in the 3rd quarter valued at $62,000. Neo Ivy Capital Management bought a new position in Omnicell in the 3rd quarter valued at $78,000. Fifth Third Bancorp increased its stake in shares of Omnicell by 143.2% in the 3rd quarter. Fifth Third Bancorp now owns 2,230 shares of the company’s stock valued at $100,000 after buying an additional 1,313 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Omnicell by 110.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,392 shares of the company’s stock worth $153,000 after acquiring an additional 1,777 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

Shares of Omnicell stock opened at $27.86 on Tuesday. The firm has a market cap of $1.28 billion, a P/E ratio of -61.91 and a beta of 0.76. The firm’s 50-day simple moving average is $27.67 and its 200-day simple moving average is $32.24. Omnicell has a twelve month low of $25.69 and a twelve month high of $77.14. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.22 and a current ratio of 2.52.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. The company had revenue of $258.85 million for the quarter, compared to the consensus estimate of $256.00 million. As a group, research analysts expect that Omnicell will post 0.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.